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Abstract
Various home blood pressure monitors (HBPMs) are available to the public for purchase but only some are validated against
standardised protocols. This study aimed to assess whether HBPMs owned by participants taking part in a clinical trial were
validated models. The TIME study is a decentralised randomised trial investigating the effect of antihypertensive medication
dosing time on cardiovascular outcomes in adults with hypertension. No HBPMs were provided to participants in this trial
but patients were asked to report if they already owned one. We identified the model of HBPM reported by participants, then
cross-referenced this against lists of validated HBPMs produced by dabl Educational Trust and the British and Irish
Hypertension Society (BIHS). Of 21,104 participants, 10,464 (49.6%) reported their model of HBPM. 7464 (71.3%) of these
participants owned a monitor that could be identified from the participants’ entry. Of these, 6066 (81.3%) participants owned
a monitor listed as validated by either dabl (n= 5903) or BIHS (n= 5491). Some were listed as validated by both. 1398
(18.7%) participants owned an identifiable HBPM that lacked clear evidence of validation. 6963 (93.3%) participants owned
an upper arm HBPM and 501 (6.7%) owned a wrist HBPM. Validated HBPMs had a higher median online retail price of
£45.00 compared to £20.00 for HBPMs lacking clear evidence of validation. A significant number of participants own
HBPMs lacking evidence of validation.
Introduction
High blood pressure or hypertension is an important risk
factor for cardiovascular disease [1, 2] and the greatest
preventable risk factor for disability and premature death
worldwide [3]. It is well established that adequately con-
trolled hypertension reduces the risk of cardiovascular dis-
ease and all-cause mortality [4]. While non-invasive blood
pressure monitoring using auscultatory sphygmoman-
ometers and automated oscillatory blood pressure monitors
can only provide an approximation of intra-arterial blood
pressure, such methods are the mainstay of clinical diag-
nosis and management. Increasingly, hypertension guide-
lines are recognising the importance of out-of-clinic blood
pressure measurements, particularly with home blood
pressure monitors (HBPMs) as a key element in the diag-
nosis and management of hypertension [5–8].
The use of HBPMs offers several potential advantages
over clinic blood pressure measurements including the
provision of multiple readings over an extended period of
time, convenience for patients, avoidance of white coat
effect and increased awareness and interest in self-
management of hypertension amongst patients [9, 10].
Home blood pressure measurements have been found to
be more reproducible [11] and a better predictor of car-
diovascular mortality in comparison to clinic measure-
ments [12, 13]. Use of HBPMs by patients to self-monitor
blood pressure, with appropriate support (including edu-
cation and systematic titration of medication), has been
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associated with improved control compared to patients
managed with only clinic blood pressure monitoring
[14, 15].
For the advantages of hypertension self-monitoring to
be realised, it is imperative that the HBPMs used provide
accurate blood pressure measurements. Various HBPMs
are available for purchase but only some are validated
against independent standards; this may affect the accuracy
of blood pressure measurements using these monitors [16].
Often, trials investigating the efficacy of interventions
using HBPMs provide participants with validated monitors
therefore it is unclear if the findings of such trials can be
generalised to usual practice where patients may be
expected to purchase their own monitor. The recent
ACCU-RATE study reported that unvalidated monitors
owned by patients were less likely to pass standardised
static pressure testing than validated (64% pass rate vs
96%) [17].
In this study, we aim to describe the validation status of
HBPMs already owned by participants in the Treatment In
Morning versus Evening (TIME) study. Additionally, we
aim to determine if validation status of HBPM owned is




The TIME study is a prospective, randomised, open-label,
blinded end-point (PROBE) design trial investigating the
effect of antihypertensive medication dosing time on car-
diovascular outcomes in 21,104 adults with hypertension.
The TIME study is an example of a remote decentralised
clinical trial with a single central site and remote partici-
pation. Patients who were aged over 18 years, prescribed at
least one antihypertensive medication to be taken once daily
and had a valid e-mail address were eligible to enrol in the
TIME study via a secure web-portal (https://www.
timestudy.co.uk). Recruitment for the TIME study was via
advertising to eligible patients across the UK from primary
care, secondary care and from databases of individuals who
have consented to be approached for participation in
research studies. Potential participants were invited to
complete an online questionnaire which required con-
firmation of study suitability based on the inclusion and
exclusion criteria as detailed in the study protocol [18].
Following confirmation of eligibility, participants
could complete the consent and registration process online
prior to randomisation. The TIME study utilises an infor-
mation technology-based methodology to monitor patient
outcomes.
The TIME study is a registered clinical trial (EudraCT
2011-001968-21, ISRCTN18157641) with ethical approval
(East of Scotland Research Ethics Service 11/AL/0309).
Data collection
All TIME study participants were asked if they owned an
HBPM and if they would be willing to provide measure-
ments for the study. A drop-down menu with commonly
used HBPM models was provided for participants to select
from. In this menu, an option labelled “Other Not Speci-
fied” was available for participants owning an HBPM
model not featured in the drop-down menu. Patients who
selected the option “Other Not Specified” had access to a
free-text field to input the model of their HBPM. All free-
text entries were subsequently interpreted and matched
against commercially available models.
Due to the unstructured nature of free-text entries, sev-
eral entries from participants could not be deciphered to
accurately determine the HBPM model in use. These entries
were therefore not included for subsequent analysis. A
study schematic with numbers of participant entries mat-
ched to a HBPM model is shown in Fig. 1.
To determine the validation status of HBPMs in use,
identified models were cross-referenced against lists of
validated HBPMs produced by dabl Educational Trust [19]
and the British and Irish Hypertension Society (BIHS) [20].
Both the dabl Educational Trust and BIHS have differing
reporting practices, as shown in Fig. 2, but adhere to
recommending HBPMs which pass at least one of the
testing standards established by the British Hypertension
Society protocol [21], European Society of Hypertension
(ESH) International protocol (2002) [22] or ESH Interna-
tional protocol (2010) [23]. In this study we classified
HBPMs as having clear evidence of validation if it was
recommended as validated by either BIHS or the dabl
Educational Trust. HBPMs which were reported as having
questionable evidence or not reported by either organisa-
tion, were classified as having no clear evidence of
validation.
To determine the influence of participants’ socio-
economic status on choice of HBPM, we derived socio-
economic deprivation scores, based on participants’
residential postcode. Participants in the TIME study were
recruited from different parts of the UK (i.e. England,
Wales, Scotland and Northern Ireland). Postcodes were
used to assign each participants’ individual index of mul-
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● Wales (https://gov.wales/statistics-and-research/welsh-
index-multiple-deprivation/?lang=en);
● Northern Ireland (https://www.nisra.gov.uk/statistics/
deprivation/northern-ireland-multiple-deprivation-mea
sure-2017-nimdm2017).
The socioeconomic deprivation decile scores from the
different constituent countries of UK, were aggregated as a
combined IMD decile score. Subsequently, participants
were classified into either being in the less deprived (IMD
decile 6–10) or more deprived (IMD decile 1–5) socio-
economic groups for analysis. Country-specific variations in
IMD decile scores, were adjusted for with the inclusion of
the country of residence as a separate variable in multi-
variate analysis.
A web search was performed to determine the online
retail price of identified HBPMs. The lowest online retail
price for a HBPM was searched (April 2018) on trusted
web sources (e.g. www.bloodpressureuk.org) and com-
mon online retailers (e.g. www.amazon.co.uk). If no price
could be found, a wider web search was performed to
identify a listed price. The lowest online retail price for
new (first-hand) HBPMs were included for analysis.
HBPMs with no available price were excluded from the
cost analysis.
Statistical analysis
Data was summarised as number of patients and percentage
for categorical variables. Prices of HBPMs are reported as
medians with Kruskal–Wallis test and Dunn’s post hoc test
performed to determine significant differences. A logistic
regression model was constructed to determine participant-
level and HBPM related factors which are associated with
the reported HBPM having clear evidence of validation. All
analysis was performed on RStudio version 3.5.1 (RStudio,
Fig. 2 A flow diagram explaining the reporting of HBPM validation status by dabl Education Trust and the BIHS. Diastolic blood pressure
(DBP), Systolic blood pressure (SBP), British Hypertension Society (BHS), European Society of Hypertension (ESH), Home blood pressure
monitor (HBPM).
Fig. 1 Flowchart showing
derivation of study population
used in this analysis. Number
of individual participants (N),
Home blood pressure monitor
(HBPM).
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Inc, Massachusetts, USA). A p value < 0.05 was considered
to be statistically significant.
Results
Description of HBPMs owned
A total of 21,104 participants were randomised to the TIME
study. Participants recruited to the TIME study were from
England (n= 18,532; 87.8%), Scotland (n= 1816; 8.6%),
Wales (n= 750; 3.6%) and Northern Ireland (n= 6;
0.03%). A total of 11,434 (54.2%) participants reported
owning an HBPM and 10,464 (49.6%) reported the model
of HBPM owned.
From the participants who reported their model of
HBPM, 4909 (46.9%) owned a model which was available
for selection from the provided drop-down menu in the
TIME study web interface. The remaining 5555 (53.1%)
participants had selected the option “Other Not Specified”
gaining access to input their model of HBPM owned in the
free-text entry field. Of these, 3000 entries either could not
be interpreted or were left unfilled and the underlying
HBPM model therefore not identified. The exact model of
HBPM owned was determined for 7464 (71.3%) partici-
pants. A total of 261 different HBPM models were reported
of which 187 were upper arm models and 74 were wrist
models. Most participants, 6963 (93.3%), owned an upper
arm HBPM with 501 (6.7%) participants owning a wrist
HBPM. Only one participant reported owning a manual
HBPM with the remainder owning an automatic HBPM.
Five common models comprised just over half (53%) of
identifiable HBPMs, and 49% were built by one dominant
manufacturer. The prices of 175 (67.0%) HBPM models
owned by 7077 participants were identified. The median
price of an HBPM owned by participants in the TIME study
was £45.00. The median price of wrist HBPMs was sig-
nificantly higher than upper arm HBPMs (£120.00 vs
£45.00; p < 0.001).
Amongst the 7464 participants whose HBPM models
were identified, the postal codes were available for 7395
(99.1%) participants. Of these, 1799 (24.3%) participants
resided in more deprived socioeconomic regions (IMD
deciles 1–5).
Validation of HBPMs owned
From a total of 7464 participants, whose HBPM models
were identified, 6066 (81.3%) participants owned a model
which had evidence of validation. Of these, the HBPMs
owned by 5903 (79.1%) and 5491 (73.6%) participants had
evidence of validation reported in the dabl Educational
Trust and BIHS databases respectively. The median price of
validated HBPMs was significantly higher than that of
HBPMs lacking clear evidence of validation (£45.00 vs
£20.00, p < 0.001). The median expenditure on HBPMs was
£45.00 amongst participants from both less deprived
regions (IMD deciles 6–10) and more deprived regions
(IMD deciles 1–5).
A multivariate logistic regression model based on parti-
cipants’ socioeconomic deprivation group (less deprived vs
more deprived), type of HBPM (upper arm vs wrist),
median price of HBPM, degree of participant engagement
with self-reporting of BP readings (measured by whether a
participant had submitted at least one set of systolic and
diastolic blood pressure readings) and country of residence
at enrolment was constructed (Table 1). At least one set of
systolic and diastolic blood pressure readings were available
from 5389 (72.2%) participants of which 4401 owned a
validated monitor. Participants who purchased upper arm
HBPMs (adjusted OR, 5.08 (95% CI, 3.83–6.75)) or
HBPMs costing greater than the median online price of
£45.00 (adjusted OR, 14.4 (95% CI, 11.2–18.7)) or whose
socioeconomic status could not be derived (adjusted OR,
2.62 (95% CI, 1.26–5.96)) were significantly more likely to
own a model having clear evidence of validation. Partici-
pants who owned HBPMs with no available online retail
price (adjusted OR, 0.08 (95% CI, 0.06–0.11)) or resided in
Scotland (adjusted OR, 0.65 (95% CI, 0.50–0.83)) com-
pared to England at the time of study enrolment were sig-
nificantly less likely to own a model with evidence of
validation.
Discussion
This study offers a pragmatic insight into the type of
HBPMs used by patients with hypertension in the UK. A
large variety of HBPMs, most commonly manufactured by
Omron, are used by the TIME study participants. Upper arm
HBPMs are more commonly used in comparison to wrist
HBPMs with the latter observed to have higher median
price. Wrist HBPMs offer an advantage of smaller size and
greater ease of use compared to upper arm HBPMs [24, 25].
The more recent introduction of wrist HBPMs to the mar-
ket, higher price points, and lack of endorsement in
guidelines may also explain why wrist HBPMs were less
prevalent than upper arm models.
Most participants who reported their HBPM model,
owned a model validated by the dabl Education Trust or
BIHS. However, a significant number (n= 1398; 18.7%)
owned a HBPM lacking clear evidence of validation.
Information on the validation status of a HBPM may be
omitted by manufacturers on their packaging or product
information leaflets, or, where present, may be obscured by
excessive branding. Phrases such as “clinically proven” or
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“clinically tested” do not equate to validation against
independent standards and may entice the uninformed
patient into inadvertently purchasing a HBPM without
validation [26]. Additionally, statements such as “FDA
cleared” are included under the description of some unva-
lidated HBPMs. The FDA approval certification for HBPMs
is to assure device safety in operation rather than affirming
the clinical accuracy of HBPMs [27].
HBPMs lacking clear evidence of validation had a
lower median price than validated HBPMs in our study.
Some patients may have been inclined to purchase the
former, unaware that guidelines recommend the use of
validated monitors. A recent study investigating the
validation status of HBPMs in use by patients in Turkey
reported that only 36% had evidence of validation
reported by the dabl Educational Trust or BIHS websites
[28] however the English ACCU-RATE study found 69%
[17]. The proportion of validated monitors in use was also
higher in our cohort of patients. This may reflect national
differences in regulations for the import and sale of
HBPMs. With increasing numbers of medical devices
being bought online, it becomes easier for manufacturers
to bypass local regulations to market unvalidated monitors
to patients [29]. A study investigating the validation of
HBPMs available for purchase through the internet found
that only 66 out of 124 websites offered at least one
validated HBPM and of these, only 6 sites had informa-
tion on the exact validation protocol passed by the HBPM
on sale [26].
Wrist HBPMs were significantly associated with a
reduced likelihood of having a clear evidence of validation.
Wrist HBPMs require strict adherence to posture with the
monitor needing to be placed at heart level to achieve
accurate measurements. Even validated wrist HBPMs with
position sensors have been observed to overestimate BP
measurements in patients self-monitoring BP [30]. Given
this reputation of wrist HBPMs for inaccuracy [31], it is
possible that several manufacturers may have chosen not to
submit their monitors for validation procedure prior to
marketing.
Table 1 HBPM and participant
characteristics associated with
the likelihood of HBPM model




Univariate analysis Adjusted analysis
Yes (%) No (%) OR 95% CI P value OR 95% CI P value
Subgroup HBPM characteristics
Type of monitor
Wrist 281 (4.6) 220 (15.4) Reference




3300 (54.4) 1004 (71.8) Reference
> than median
(£45.00)
2700 (44.5) 73 (5.2) 11.3 (8.89–14.5) <0.001 14.4 11.2–18.7 <0.001
Not known 66 (1.1) 321 (23.0) 0.06 (0.05–0.08) <0.001 0.08 0.06–0.11 <0.001
Participant characteristics
At least 1 BP reading available
No 1665 (22.3) 410 (5.5) Reference
Yes 4401 (59.0) 988 (13.2) 1.1 (0.96–1.25) 0.157 0.95 0.82–1.10 0.512
Socioeconomic status
More depriveda 1439 (23.7) 360 (25.7) Reference
Less deprivedb 4569 (75.3) 1027 (73.5) 1.11 (0.97–1.27) 0.117 1.13 0.97–1.31 0.118
Not known 58 (1.0) 11 (0.8) 1.31 (0.71–2.68) 0.407 2.62 1.26–5.96 0.015
Country of residence at enrolment
England 5486 (73.5) 1238 (16.6) Reference
Scotland 398 (5.3) 117 (1.6) 0.77 (0.62–0.96) 0.016 0.65 0.50–0.83 0.001




aMore deprived (IMD decile 1–5).
bLess deprived (IMD decile 6–10).
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Although validated HBPMs were of significantly higher
price than HBPMs lacking clear evidence of validation, the
ownership of the former was not associated with the parti-
cipants’ socioeconomic status (derived from residential
postcode). In fact, the median prices of HBPMs owned by
participants from different socioeconomic groups were lar-
gely similar. This suggests that spending on HBPMs by
participants in our study may be independent of socio-
economic status. For this group of patients, additional
information on the importance of choosing validated
HBPMs may prove more effective than financial incentives
in guiding purchase decisions.
Several participants (n= 809) had entered the vendor’s
name (e.g. “Lloyds” or “Boots”) or model of BP cuff used
or indicated that they did not know/could not find the model
of their HBPM. Several others had only indicated the brand
name (e.g. Omron or Braun) with no indication of the
specific model. This uncertainty about underlying model
may be due to over-branding or unclear labelling. Given
that participants were unable to identify their model, this
could suggest that factors other than validation status
(which requires model identification) such as price, vendor
recommendations, attractiveness of packaging or additional
features (e.g. mobile application interconnectivity) are more
important to patients when choosing a monitor. This further
reiterates the need for improved education on choosing
validated HBPMs for patients both by healthcare profes-
sionals and medical device vendors.
Strengths and weaknesses of the study
A major strength of this study is that it describes the HBPM
choices of a large group of patients with hypertension
across the UK. Having a free-text entry box with a character
limit hindered the identification of a significant number of
HBPMs which otherwise would have added to the strength
of our observations. This study has an inherent selection
bias as it only included UK participants enroled in a long-
term internet-only clinical trial. Like most randomised
controlled trial cohorts, these participants represent a
population who may be more engaged in their own
healthcare [32]. Additionally, the online nature of the TIME
study and higher recruitment from less deprived regions, is
likely to have resulted in under-representation of people
from lower socioeconomic groups. In this study we did not
investigate the age or calibration status of HBPMs used by
participants; both of these factors have been reported to
affect the accuracy of BP measurements even in validated
devices [33]. Prices of older HBPMs are likely to have been
higher at the time of original purchase.
At the time of analysis, dabl and BIHS were the only
publicly accessible databases of HBPMs validation status.
Since 2019, STRIDE BP, an international scientific non-
profit organisation, has listed validated HBPMs on its
website, www.stridebp.org [34]. The continued transparent
clinical and scientific oversight of the STRIDE BP and
BIHS HBPM listings makes them most suitable for this type
of research in future.
Future research
Participants in the TIME study who reported owning their
own HBPM were invited to submit home blood pressure
measurements obtained using their HBPM through the
TIME study web interface at intervals throughout the study.
These measurements could be analysed to look for any
evidence of variation in systolic and diastolic pressures
associated with validation status. A qualitative study
exploring the decision-making process of patients with
hypertension when purchasing a HBPM may be warranted
to determine factors which could influence the choice of
HBPM. In addition, new HBPMs are becoming available,
some with additional capabilities, such as detection of atrial
fibrillation, or night-time blood pressures and it would be
interesting to re-evaluate HBPM ownership again in the
future.
Conclusion
From this study, it is evident that patients with hypertension
in the UK are using a large variety of HBPMs. Although
most participants in the TIME study are using validated
HBPMs, a significant number are using HBPMs which do
not have clear evidence of validation. Amongst participants
whose model of HBPM was identified, upper arm-type
HBPMs were more common than wrist-type HBPMs with
almost all participants using automated monitors. HBPMs
with validation were more expensive than HBPMs without
evidence of validation. However, socioeconomic status did
not appear to affect likelihood of choosing a
validated monitor. The factors which influence a patient’s
choice of HBPM remain unclear, but the public may benefit
from clearer labelling and information about validation
status of HBPM to allow them to make more informed
purchases.
Summary table
What is known about topic
● Self-monitoring with home blood pressure monitors
with guidance is associated with improved blood
pressure control.
● Various HBPMs are available for purchase but only
some are validated against independent standards.
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What this study adds
● Patients with hypertension in the UK are using a large
variety of home blood pressure monitors.
● A significant number of hypertension patients in the UK
are using home blood pressure monitors lacking clear
evidence of validation.
● Home blood pressure monitors with evidence of
validation had a significantly higher median price
compared to monitors lacking clear evidence of
validation.
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